C4 Therapeutics Share Price (NASDAQ: CCCC)

$2.6

▲

0.05

(1.96%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive C4 Therapeutics Stock chart to analyse performance

C4 Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$2.36
Today's High:$2.60
$2.60
9.42%
Downside
Day's Volatility :9.42%
Upside
0.0%
52 Weeks Low:$1.09
52 Weeks High:$7.22
$2.60
58.27%
Downside
52 Weeks Volatility :84.97%
Upside
63.99%

C4 Therapeutics Stock Returns

Period	C4 Therapeutics, Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	95.11%	3.6%	0.0%
6 Months	8.13%	-7.7%	0.0%
1 Year	-56.82%	-12.6%	0.0%
3 Years	-74.41%	10.2%	-4.1%

C4 Therapeutics, Inc Key Stats

Check C4 Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.55
Open	$2.47
Today's High	$2.6
Today's Low	$2.355
Market Capitalization	$181.5M
Today's Volume	$1.3M
52 Week High	$7.22
52 Week Low	$1.085
Revenue TTM	$34.2M
EBITDA	$-121.6M
Earnings Per Share (EPS)	$-1.59
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-52.99%

Stock Returns calculator for C4 Therapeutics Stock including INR - Dollar returns

The C4 Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

C4 Therapeutics investment value today

Current value as on today

₹48,545

Returns

₹51,455

(-51.45%)

Returns from C4 Therapeutics Stock

₹56,739 (-56.74%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards C4 Therapeutics Stock

216%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for C4 Therapeutics Stock from India on INDmoney has increased by 216% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in C4 Therapeutics, Inc

Name
Holdings %
Name
Holdings %
Wasatch Advisors LP
10.43%
Soleus Capital Management, L.P.
9.81%
Orbimed Advisors, LLC
9.60%
BlackRock Inc
7.43%
Morgan Stanley - Brokerage Accounts
5.68%
Vanguard Group Inc
4.24%

Analyst Recommendation on C4 Therapeutics Stock

Rating

Trend

Buy

73%Buy

26%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics(by analysts ranked 0 to 5 stars)

C4 Therapeutics Share Price Target

What analysts predicted

Upside of 507.69%

Target:

$15.80

Current:

$2.60

C4 Therapeutics share price target is $15.80, a slight Upside of 507.69% compared to current price of $2.60 as per analysts' prediction.

C4 Therapeutics Stock Insights

Price Movement
In the last 1 month, CCCC stock has moved up by 26.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 7.23M → 6.46M (in $), with an average decrease of 10.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -34.57M → -26.02M (in $), with an average increase of 16.3% per quarter
CCCC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 128.8%
CCCC vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 190.3%
Price to Sales
ForCCCC every $1 of sales, investors are willing to pay $5.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

C4 Therapeutics, Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$21.4M	↑ 10.42%
Net Income	$-34.1M	↑ 117.04%
Net Profit Margin	-159.48%	↓ 78.34%

	FY20	Y/Y Change
Revenue	$33.2M	↑ 55.25%
Net Income	$-66.3M	↑ 94.54%
Net Profit Margin	-199.83%	↓ 40.35%

	FY21	Y/Y Change
Revenue	$45.8M	↑ 37.93%
Net Income	$-83.9M	↑ 26.47%
Net Profit Margin	-183.23%	↑ 16.6%

	FY22	Y/Y Change
Revenue	$31.1M	↓ 32.08%
Net Income	$-128.2M	↑ 52.79%
Net Profit Margin	-412.19%	↓ 228.96%

	FY23	Y/Y Change
Revenue	$20.8M	↓ 33.25%
Net Income	$-132.5M	↑ 3.37%
Net Profit Margin	-638.34%	↓ 226.15%

	FY24	Y/Y Change
Revenue	$35.6M	↑ 71.44%
Net Income	$-105.3M	↓ 20.51%
Net Profit Margin	-295.96%	↑ 342.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.0M	↓ 6.81%
Net Income	$-28.4M	↓ 18.4%
Net Profit Margin	-933.23%	↑ 132.52%

	Q2 FY24	Q/Q Change
Revenue	$12.0M	↑ 295.06%
Net Income	$-17.7M	↓ 37.53%
Net Profit Margin	-147.56%	↑ 785.67%

	Q3 FY24	Q/Q Change
Revenue	$15.4M	↑ 27.95%
Net Income	$-24.7M	↑ 39.23%
Net Profit Margin	-160.57%	↓ 13.01%

	Q4 FY24	Q/Q Change
Revenue	$5.2M	↓ 66.3%
Net Income	$-34.6M	↑ 40.16%
Net Profit Margin	-667.82%	↓ 507.25%

	Q1 FY25	Q/Q Change
Revenue	$7.2M	↑ 39.81%
Net Income	$-26.3M	↓ 23.87%
Net Profit Margin	-363.66%	↑ 304.16%

	Q2 FY25	Q/Q Change
Revenue	$6.5M	↓ 10.71%
Net Income	$-26.0M	↓ 1.15%
Net Profit Margin	-402.6%	↓ 38.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-26.3M	↑ 184.82%

	FY20	Y/Y Change
Profit	$-45.2M	↑ 72.15%

	FY21	Y/Y Change
Profit	$42.9M	↓ 194.77%

	FY22	Y/Y Change
Profit	$23.5M	↓ 45.14%

	FY23	Y/Y Change
Profit	$13.0M	↓ 44.66%

	FY24	Y/Y Change
Profit	$35.6M	↑ 173.32%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.0M	↓ 35.54%

	Q2 FY24	Q/Q Change
Profit	$10.0M	↑ 884.29%

	Q3 FY24	Q/Q Change
Profit	$13.3M	↑ 33.58%

	Q4 FY24	Q/Q Change
Profit	$3.4M	↓ 74.36%

	Q1 FY25	Q/Q Change
Profit	$7.2M	↑ 112.2%

	Q2 FY25	Q/Q Change
Profit	$6.5M	↓ 10.71%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$55.6M	↓ 427.51%
Investing Cash Flow	$-1.6M	↓ 104.39%
Financing Cash Flow	$244.0K	↓ 87.56%

	FY20	Y/Y Change
Operating Cash Flow	$-67.2M	↓ 220.92%
Investing Cash Flow	$-190.5M	↑ 11659.57%
Financing Cash Flow	$348.9M	↑ 142904.92%

	FY21	Y/Y Change
Operating Cash Flow	$-87.0M	↑ 29.32%
Investing Cash Flow	$-189.3M	↓ 0.61%
Financing Cash Flow	$171.4M	↓ 50.88%

	FY22	Y/Y Change
Operating Cash Flow	$-105.9M	↑ 21.82%
Investing Cash Flow	$58.4M	↓ 130.86%
Financing Cash Flow	$1.1M	↓ 99.33%

	FY23	Y/Y Change
Operating Cash Flow	$-106.8M	↑ 0.85%
Investing Cash Flow	$158.3M	↑ 171.04%
Financing Cash Flow	$45.5M	↑ 3865.91%

	FY24	Y/Y Change
Operating Cash Flow	$-65.2M	↓ 39.01%
Investing Cash Flow	$-51.3M	↓ 132.38%
Financing Cash Flow	$45.3M	↓ 0.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-18.1M	↓ 24.54%
Investing Cash Flow	$-53.4M	↓ 267.15%
Financing Cash Flow	$34.6M	↓ 40.04%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-5.0M	↓ 72.55%
Investing Cash Flow	$-11.7M	↓ 78.08%
Financing Cash Flow	$135.0K	↓ 99.61%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-24.1M	↑ 385.18%
Investing Cash Flow	$162.0K	↓ 101.38%
Financing Cash Flow	$10.5M	↑ 7682.22%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-17.9M	↓ 25.7%
Investing Cash Flow	$13.7M	↑ 8338.27%
Financing Cash Flow	$112.0K	↓ 98.93%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-33.3M	↑ 85.62%
Investing Cash Flow	$29.1M	↑ 113.06%
Financing Cash Flow	$-46.0K	↓ 141.07%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-12.1M	↓ 63.78%
Investing Cash Flow	$38.9M	↑ 33.63%
Financing Cash Flow	$0.0	↓ 100.0%

C4 Therapeutics Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

C4 Therapeutics, Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
C4 Therapeutics, Inc	22.41%	8.13%	-56.82%	-74.41%	-89.82%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
C4 Therapeutics, Inc	NA	NA	NA	-1.54	-0.53	-0.23	NA	2.45
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
C4 Therapeutics, Inc	Buy	$181.5M	-89.82%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About C4 Therapeutics, Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organization	C4 Therapeutics
Employees	110
CEO	Mr. Andrew J. Hirsch M.B.A.
Industry	Health Technology

Key Management of C4 Therapeutics, Inc

Name	Title
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board
Ms. Kendra Adams	CFO & Treasurer
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Mark Mossler	Chief Accounting Officer
Ms. Paige Mahaney Ph.D.	Chief Scientific Officer
Ms. Courtney Solberg	Senior Manager of Investor Relations
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary
Ms. Kelly A. Schick	Chief People Officer

Important FAQs about investing in CCCC Stock from India :

What is C4 Therapeutics share price today?

C4 Therapeutics share price today is $2.60 as on August 30, 2025 at 1:29 am IST at the close of the market. C4 Therapeutics share today touched a day high of $2.60 and a low of $2.36.

What is the 52 week high and 52 week low for C4 Therapeutics share?

C4 Therapeutics share touched a 52 week high of $7.22 and a 52 week low of $1.09. C4 Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $2.60, lower by 63.99% versus the 52 week high.

How to invest in C4 Therapeutics Stock (CCCC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for C4 Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in C4 Therapeutics Shares that will get you 0.5769 shares as per C4 Therapeutics share price of $2.60 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy C4 Therapeutics Stock (CCCC) from India?

Indian investors can start investing in C4 Therapeutics (CCCC) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in C4 Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on C4 Therapeutics share’s latest price of $2.60 as on August 30, 2025 at 1:29 am IST, you will get 3.8462 shares of C4 Therapeutics. Learn more about fractional shares .

What are the returns that C4 Therapeutics has given to Indian investors in the last 5 years?

C4 Therapeutics stock has given -89.82% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?